Trial NCT04479163
Publication Libster R, N Engl J Med, 2021
Primary outcome on the report: Development of severe respiratory disease defined as a respiratory rate (RR)≥ 30 and/or an O2 sat < 93% when breathing room air determined between 12 hours after infusion of the investigational product (IP) and day 15 of study participation

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.